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ABSTRACT 
Objective: To validate and apply a new and easy zero-crossing derivative method for the simultaneous determination of naproxen sodium and 
acetaminophen in fixed-dose combinations formulations. 
Methods: Measurement was achieved using the first-derivative (1D) signals at 243.42 nm for naproxen sodium and at 297.10 nm for 
acetaminophen. The method was validated according to International Conference on Harmonization (ICH) guidelines and was used to obtain the 
dissolution profiles (USP Apparatus 2, 75 rpm and 900 ml of 0.1 M phosphate buffer pH 7.4) of five generic products and the reference product 
Febrax® (275/300 mg of naproxen sodium and acetaminophen, respectively). Dissolution data: percent of drug dissolved at 60 min, mean 
dissolution time (MDT) and dissolution efficiency (DE) were compared by a univariate one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparisons test. Differences were considered significant if *P<0.05
Results: The method was linear (R
. Additionally, data were adjusted to different kinetic models. 
2>0.99, *P<0.05) in the range of 10–50 µg/ml and 100–300 µg/ml for naproxen sodium and acetaminophen, 
respectively. The within-day and between-day precision and accuracy were within the acceptable criteria (relative standard deviation
Conclusion: 
 (RSD)<3% 
and 100±3%). Significant differences in MDT and DE values from all studies products were found (*P<0.05). All dissolution profiles were adjusted to 
Weibull’s kinetics and significant differences in Td values were found (*P<0.05). 
The proposed derivative spectrophotometry
Keywords: Naproxen sodium, Acetaminophen, First-order derivative spectroscopy, Zero-crossing method, Fixed-dose combinations formulations. 
 method can be used for the simultaneous determination of naproxen sodium and 
acetaminophen in dissolution studies. The method is rapid, simple, accurate, and precise without the need of high cost investment. 
 
INTRODUCTION 
Naproxen sodium [(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid 
sodium salt] is a non-steroidal anti-inflammatory drug (NSAID) used in 
pain treatment, fever and inflammation caused by migraine, rheumatoid 
arthritis and degenerative joint diseases. It is also used for the primary 
dysmenorrheal, fig. 1. Due to poor solubility of naproxen (weak acid with 
pka = 4.15) naproxen sodium is prepared to enhance the dissolution 
properties of naproxen. According to Biopharmaceutical Classification 
System (BCS) drugs with low solubility/high permeability belong to 
Class II drugs [1]. For this kind of drugs, dissolution is the rate-limiting 
step for absorption and a significant in vitro/in vivo correlation (IVIVC) is 
expected. Acetaminophen, also named as paracetamol [N-Acetyl-p-
aminophenol], is an effective and safe analgesic-antipyretic drug widely 
used for the relief of mild to moderate pain, fig. 1. Acetaminophen is a 
Class III drug [2] with high solubility/low permeability and by the 
previously reported information there is a monograph that suggests the 
waiver of bioequivalence studies by in vitro dissolution studies [3]. The 
combination of naproxen sodium and acetaminophen (as fixed-dose 
combinations formulations) is widely used as over-the-counter products 
and it is used for the treatment of symptomatic pain and fever. 
In vitro dissolution studies are useful to assess the lot-to-lot quality 
of pharmaceutical formulations, changes in their manufacturing 
process and prediction of in vivo performance of some drugs. United 
States (US) Pharmacopeia describes by separate the in vitro 
dissolution test for naproxen sodium and acetaminophen tablets [4] 
but to date, no official dissolution method is described for naproxen 
sodium and acetaminophen in fixed-dose combinations formulations 
[5]. The development of fixed-dose combinations products is 
becoming increasingly from a public health perspective and has 
advantages when all the actives contribute to the overall therapeutic 
effect. Dissolution studies for this kind of formulations are data 
required for approval of fixed-dose combinations [6]. 
 
There is enough information for the individual quantification of 
naproxen sodium and acetaminophen by different analytical 
methods [7, 8]. However, information about simultaneous 
determination of these drugs in the same formulation is scarce. A 
high-performance liquid chromatography (HPLC) method was 
previously reported [9]. Electrochemical determination was used for 
simultaneous determination of both drugs in pharmaceutical 
formulations [10] and biological fluid [11] however, for all these 
techniques special equipment is required. On the other hand, 
spectroscopic methods are widely used for identification of metal 
ions, pharmaceutical compounds and food ingredients [12‒14]. 
Derivative spectrophotometry is an economic and useful technique 
for the suppression of additive interferences due to compounds 
mixture with overlapping spectra. Despite these advantages, none 
derivative spectrophotometry methodology for simultaneous 
quantification of naproxen sodium and acetaminophen in fixed-dose 




1: Chemical structures of naproxen sodium (N) and 
acetaminophen (A) 
The purpose of this study was to validate and apply a simple, 
economic and rapid zero-crossing 1D spectrophotometric method for 
the simultaneous determination of in vitro dissolution profiles of 
naproxen sodium and acetaminophen in fixed-dose combinations 
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generic formulations and to compare their dissolution profiles with 
the dissolution profiles of naproxen sodium and acetaminophen 
from the reference product Febrax® (Mexico). The method was 
validated according to ICH guidelines and dissolution profiles were 
compared by model-dependent and-independent approaches. 
MATERIALS AND METHODS 
Materials 
Five fixed-dose generic formulations were used in this study. 
Naproxen sodium and acetaminophen doses were 275/300 mg, 
respectively. Different letters were assigned to each drug product (A, 
B, C, D, and E). Dissolution profiles of generic drugs were compared 
to dissolution profile of the Mexican reference (R) product Febrax® 
(Siegfried Rhein, S. A. de C. V., Mexico). Phosphate salts were 
purchased from J. T. Baker-Mexico. Naproxen sodium and 
acetaminophen standards were purchased from Sigma-Aldrich Co. 
(St. Louis MO, USA). All dissolution medium were filtered through 
glass microfiber filters (Whatman®, UK). 
Content uniformity and assay 
Content uniformity and assay tests were performed by HPLC with all 
fixed-dose combinations formulations, according the procedures 
described by Singh et al. [9]. 
Standard solutions 
Stock solutions of naproxen sodium and acetaminophen in 0.1 M 
phosphate buffer pH 7.4 were separately prepared by dissolving 10 
mg of naproxen sodium in 100 ml of 0.1 M phosphate buffer pH 7.4 
and 25 mg of acetaminophen in 25 ml of 0.1 M phosphate buffer pH 
7.4. Standard solutions were prepared by serial dilutions of the stock 
solutions to contain the required concentrations for the calibration 
curves. Naproxen sodium and acetaminophen calibration curves in 
0.1 M phosphate buffer pH 7.4 were prepared in the concentrations 
range of 10–50 µg/ml and 100–300 µg/ml, respectively. 
Instruments 
For dissolution studies, USP Apparatus 2 (Sotax AT-7 Smart, 
Switzerland) rotating paddle was used. For spectrophotometric 
measurement, a double beam UV/VIS spectrophotometer (Perkin 
Elmer Lambda 35, Waltham MA, USA) with 0.1 cm quartz cells was 
utilized. The operating conditions for UV analysis were 1D mode with 
scan speed 240 nm/min, slit width 2 nm and sampling interval 1 nm. 
The amounts of naproxen sodium and acetaminophen dissolved 
were determined at 243.42 and 297.10 nm respectively, with 
reference to standard calibration curves. 
Analytical method validation 
The proposed 1D spectrophotometric method was validated 
according to ICH guidelines [15]. Method linearity, accuracy, 
precision were determined and drugs stability in dissolution 
medium was evaluated. 
Linearity 
To verify the validation of Beer’s law, three series of calibration curves 
in 0.1 M phosphate buffer pH 7.4 were plotted using the 1D spectra in 
the range of the calibration curve of each drug. Data obtained were 
fitted by linear regression analysis and the coefficients of regression 
and regression ANOVA were calculated. The response versus naproxen 
sodium or acetaminophen concentration proportionality was 
demonstrated for each drug by calculating the percentage RSD: 
[((standard deviation)/mean) × 100] of the response factor across the 
entire range of the calibration curve. 
Accuracy and precision 
In order to verify the accuracy and precision of the proposed derivative 
analysis, the added standard method was used, thus matrix effects can 
easily be removed. This method can be used for resolving binary 
mixtures in complex samples with unknown matrices as commercial 
oral dosage forms have. Twenty tablets were accurately weighed and 
milled in a mortar; then, quantities of powder of naproxen 
sodium/acetaminophen tablets plus a quantity of naproxen sodium or 
acetaminophen standard (10 mg) to finally give the equivalent of 80, 100 
and 120% of the dose of each drug, were separately dissolving in 900 ml 
of 0.1 M phosphate buffer pH 7.4 at 37.0±0.5 ºC. The USP Apparatus 2 at 
75 rpm was used. At 60 min, the amounts of naproxen sodium and 
acetaminophen dissolved in each sample were calculated with reference 
to a calibration curve prepared on the day of the experiment. Each 
determination was performed in triplicate. The percentage relative error 
(RE): [((found–added)/added) × 100] was taken as a measure of the 
accuracy and the RSD as a measure of precision. Experiments were done 
in three consecutive days. 
Stability 
Stability of analytical solutions was evaluated analyzing two 
solutions of naproxen sodium (15 and 45 µg/ml) and two solutions 
of acetaminophen (140 and 260 µg/ml) prepared in 0.1 M phosphate 
buffer pH 7.4. These solutions are a low and a high concentration of 
the calibration ranges and were analyzed by the proposed 1D 
spectrophotometric method at 0, 24 and 48 h after stored at 4 ºC. At 
24 and 48 h, the percentage absolute difference (AD): [((initial–
final)/initial) × 100] recovered of each drug was determined. 
Dissolution studies 
Naproxen sodium and acetaminophen dissolution profiles were 
performed using USP Apparatus 2. Tablets were added on 900 ml of 
0.1 M phosphate buffer pH 7.4 at 37.0±0.5 ºC as dissolution medium 
(n = 12). Prior to use, the dissolution medium was deareated by 
vacuum. Rotational speed of 75 rpm was tested. 10 ml of filtered 
samples were withdrawn at 10, 20, 30, 45, and 60 min without 
replacement of dissolution medium. The samples were then 
analyzed by the 1D proposed methods to know the rate and extent of 
dissolution of naproxen sodium and acetaminophen from all fixed-
dose combinations formulations used. 
Naproxen sodium and acetaminophen
Data analysis 
 dissolution profiles were 
compared with similarity factor f2
 
 [16]. Additionally, dissolution 
data of each product were used to calculate model-independent 
parameters: % dissolved at 60 min, MDT [17] and DE [18]. The 
values of these parameters from generic drugs were compared with 
the reference product values by ANOVA followed by Dunnett’s or 
Dunnett’s T3 multiple comparisons test as appropriate. Data 
analysis was carried out using SPSS software (Version 17.0). 
Differences were considered significant if *P<0.05. 
Table 1: Content uniformity and assay results. Mean, n = 10 
Product Drug Content uniformity (min–max) Assay (%) 
R N (98.65–102.45) 100.44 
A (99.25–103.07) 101.05 
A N (99.35–104.14) 102.15 
A (96.48–101.13) 100.34 
B N (101.80–104.50) 102.96 
A (98.49–101.10) 99.61 
C N (100.53–102.24) 101.47 
A (98.90–100.59) 99.83 
D N (100.97–104.56) 102.64 
A (100.21–103.77) 101.87 
E N (101.19–102.27) 101.65 
A (97.67–98.72) 98.12 
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Moreover, in order to evaluate the release kinetics of naproxen sodium 
and acetaminophen from the studied products, dissolution data were 
fitted to different kinetic models: First order, Higuchi, Korsmeyer-
Peppas, Hixson-Crowell and Weibull. The model with highest 
determination coefficient (R2adjusted) and minimum Akaike Information 
Criterion (AIC) was chosen as the best fit [19]. Data analysis was 
carried out using Excel add-in DDSolver program [20]. To compare 
dissolution profiles with model-dependent methods a parameter 
derived from the best fit model was compared with a univariate one-
way ANOVA followed by Dunnett’s or Dunnett’s T3 multiple 
comparisons test. Differences were considered significant if *P<0.05. 
RESULTS AND DISCUSSION 
Content uniformity and assay 
 
Fig. 2: Zero-order spectra of 30 µg/ml of N, 150 µg/ml of A and their 
mixture (N+A) at the same concentrations in 0.1 M phosphate 
buffer pH 7.4 (a) and first-derivative spectra of the same solutions 
(b). Small vertical lines indicate zero-crossing points 
 
The percentages of naproxen sodium and acetaminophen on the 
assay and content uniformity tests are shown in table 1. 
 
1D spectrophotometric method 
The zero-order spectra of naproxen sodium (30 µg/ml) and 
acetaminophen (150 µg/ml) standard solutions in 0.1 M phosphate 
buffer pH 7.4 were separately and combined measured at 200–320 
nm using 0.1 M phosphate buffer pH 7.4 as blank, fig. 2a. The zero-
order spectra demonstrated a marked overlapping. As a result, 
simultaneous direct spectroscopy determination of naproxen 
sodium and acetaminophen in fixed-dose combination products was 
not possible. Then, the 1D spectra of these solutions was obtained, 
fig. 2b. As seen in fig. 2b, the 1D spectra of naproxen sodium revealed 
six zero-crossing points for acetaminophen determination (230.51, 
253.29, 262.41, 266.96, 271.27 and 297.10 nm) and the 1D spectra of 
acetaminophen revealed two zero-crossing points for naproxen 
determination (216.46 and 243.42 nm). 
The 1D spectra of naproxen sodium (10–50 µg/ml) and acetaminophen 
(100–300 µg/ml) standard solutions were determined, fig. 3. The 
suitable zero-crossing points were selected based on the best linear 
response to the naproxen sodium concentration in the presence of 
acetaminophen or the acetaminophen concentration in the presence of 
naproxen sodium. Only the 1D response at 243.42 and 297.10
 
Fig. 3: First-derivative spectra of 10–50 µg/ml of N and 100–300 
µg/ml of A in 0.1 M phosphate buffer pH 7.4. Vertical lines 
indicate 243.42 and 297.10 nm, respectively 
 
 nm were 





The mean regression equation from three standard calibration curves 
was: y = 0.0065x+0.0131 for naproxen sodium and y = 0.0003x+0.0063 
for acetaminophen. Both linear regressions were significant (R2 = 0.99; 
*P<0.05). The RSD values of response factor were 2.3 and 2.0% for 
naproxen sodium and acetaminophen ranges, respectively. 
Accuracy and precision 
In order to prove the accuracy and precision of the proposed 1
 
D 
spectrophotometric method, analysis of varying percentage of dose 
of each drug was carried out for three days (n = 3/d). The within-day 
and between-day precision and accuracy were calculated, table 2. 
The RSD obtained was in the range of 0.81–2.84% and the RE was 
lower than 1.20% for both drugs which indicate good accuracy and 
precision of the method. 
Table 2: Accuracy and precision data for simultaneous determination of N and A by first-order derivative spectroscopy. Mean±SD 
  Within-day (n = 3) Between-day (n = 9) 
Drug/dose (mg) Added (mg) Found (mg) RSD (%) RE (%) Found (mg) RSD (%) RE (%) 
N/275 221.29 221.79±1.98 0.89 0.23 221.09±2.57 1.16 ‒0.09 
277.27 279.02±2.25 0.81 0.63 278.13±3.22 1.84 0.49 
330.86 333.18±4.01 1.20 0.70 335.17±4.14 1.23 1.20 
A/300 241.20 240.10±1.98 0.82 ‒0.46 237.30±4.63 1.95 ‒1.50 
299.81 301.03±8.56 2.84 0.41 303.25±5.80 1.91 1.03 
360.23 360.53±3.73 1.04 0.08 359.12±7.08 1.97 ‒0.52 
Medina et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 5, 183-188 
186 
Table 3: Absolute difference (%) respect zero time to evaluate stability at 4ºC
Drug 
 of N and A in 0.1 M phosphate buffer pH 7.4. Mean, n = 6 
Conc. (µg/ml) 24 h 48 h 
N 15 3.73 7.54 
45 2.84 8.08 
A 140 0.96 4.16 
260 0.29 4.46 
 
 
Fig. 4: Dissolution profiles from fixed-dose combinations 
formulations obtained with the proposed 1D spectrophotometric 
method. Error bars were omitted for clarity. Mean, n = 12 
 
Stability 
The stability of the 1D spectrophotometric method was assessed 
analyzing two solutions of naproxen sodium and two solutions of 
acetaminophen (low and high concentrations for each one). AD values 
at 24 and 48 h are shown in table 3. As seen in table 3, both drugs 
solutions were less stable at the second day of have been prepared. 
Data obtained indicate good linearity, accuracy and precision of the 
proposed zero-crossing derivative method for simultaneous 
determination of naproxen sodium and acetaminophen in fixed-dose 
combinations formulations. According to complementary ICH 
guideline [21], limit of detection and limit of quantitation are 
characteristics not normally evaluated in dissolution assays. For 
both drugs, lack of linearity, accuracy, and precision was determined 
working out of the proposed range for the calibration curves. 
D
Dissolution studies 
issolution profiles of naproxen sodium and acetaminophen obtained 
with USP Apparatus 2 are shown in fig. 4. Dissolution rate of both 
drugs, from product R, was slower than the studied generic products. 
Both drugs were completely dissolved until 60 min. Naproxen sodium 
and acetaminophen dissolution profiles were compared with 
similarity factor f2, fig. 5. Only dissolution profiles of naproxen sodium 
and acetaminophen from generic products B and D showed similar 




Fig. 5: Similarity factor f2 calculated with dissolution data of 
naproxen sodium (grey bars) and acetaminophen (white bars) 




D spectroscopic method was successfully applied for simultaneous 
determination of naproxen sodium and acetaminophen without 
interference of each other. The method was applied to routine in 
vitro dissolution studies. Almost all fixed-dose combinations 
formulations achieved 100% dissolved at 60 min and in all sampling 
times the RSD was lower than 10%. 
Table 4: Percentage dissolved at 60 min and dissolution parameters MDT and DE. Mean±SEM, n = 12. *P<0.05 
Drug Product % Diss. at 60 min MDT (min) DE (%) 
R N 100.56±0.82 18.92±0.26 68.86±0.74 
A 107.14±1.09* 10.67±0.33* 88.04±0.63* 
B 100.52±0.90 15.69±0.34* 74.22±0.74* 
C 102.61±1.59 9.64±0.39* 86.05±0.93* 
D 102.26±1.44 16.13±0.24* 84.08±4.13* 
E 102.51±0.57 9.59±0.23* 90.00±2.78* 
R A 96.35±0.69 21.12±0.45 62.44±0.90 
A 100.90±1.45 12.77±0.27* 79.44±1.30* 
B 96.20±1.43 16.57±0.29* 69.68±1.37 
C 97.98±0.40 9.91±0.36* 81.79±0.63* 
D 100.05±0.76* 19.79±0.27* 79.51±4.29* 
E 97.14±0.82 10.61±0.27* 82.50±3.52* 
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Model-independent comparisons 
% dissolved at 60 min, MDT and DE mean values±standard error 
medium (SEM) for products under study are shown in table 4. 
Considering model-independent comparisons significant differences 
in dissolution profiles of all fixed-dose combination generic drugs 
were found (*P<0.05) except for DE value of acetaminophen from 
generic product B. 
In order to compare the in vitro dissolution data of naproxen sodium 
and acetaminophen from fixed-dose combinations formulations, 
model-independent parameters MDT and DE were calculated. These 
parameters have been proposed as adequate parameters for some 
IVIVC levels [22]. IVIVC Level B represents a relationship between 
MDT and the mean residence time, both calculated by statistical 
moments theory. On the other hand, Level C represents a single 
point correlation between one dissolution time point (t50%, t90%, etc.) 
to one pharmacokinetic parameter such as area under the curve, 
Cmax or Tmax. DE was taken by some authors as a suitable parameter 
that expresses global drug dissolution performance useful for 
comparison of in vitro dissolution profiles [18]. 
Model-dependent comparisons 
In order to describe the naproxen sodium and acetaminophen 
release kinetics from fixed-dose combinations formulations, data 
were fitted to several equations and results are shown in table 5. 
Considering established criteria to choose the best kinetic model 
(highest R2 adjusted and lowest AIC values) only naproxen sodium in 
products A, B and E as well as acetaminophen in products A, B, D, 
and E better fitted to Weibull̓s model. Acetaminophen in product R 
better adjusted to Makoid-Banakarʼs equation. According to Costa et 
al., [23] Weibull̓ s equation can be successfully applied to almost all 
kind of dissolution curves and is commonly used in these studies. 
Due to several formulations adjusted to Weibull ʼs model and R2 adjusted
 
 
values of both drugs in product R were>0.99 in this work 
comparison of dissolution profiles by a model-dependent approach 
was made analyzing the derived parameter (Td) from Weibullʼs 
function. Td value can be calculated with α and β values and is 
equivalent to the MDT value calculated with statistical moments. 
Significant differences in Td values for both drugs and between all 
fixed-dose combinations generic drugs and product R were found 
(*P<0.05), table 6. 
Table 5: Criteria used for the selection of the best kinetic model. Mean, n = 12 
Product First-order Higuchi Korsmeyer-Peppas Hixson-Crowell Makoid-Banakar Weibull 
R2 adjusted 
naproxen sodium 
R 0.9950 0.9474 0.9786 0.9933 0.9975 0.9969 
A 0.9796 0.5752 0.9419 0.9695 0.9695 0.9825 
B 0.9902 0.8707 0.9621 0.9913 0.9913 0.9933 
C 0.9890 0.4246 0.9857 0.9889 0.9889 0.9891 
D 0.9578 0.8819 0.9092 0.9756 0.9756 0.9692 
E 0.9900 0.5439 0.9657 0.9855 0.9855 0.9904 
acetaminophen 
R 0.9920 0.9636 0.9711 0.9953 0.9979 0.9971 
A 0.9890 0.6596 0.9604 0.9557 0.9777 0.9914 
B 0.9819 0.8909 0.9433 0.9801 0.9926 0.9985 
C 0.9771 0.4551 0.9774 0.8724 0.9703 0.9830 
D 0.9335 0.8816 0.8779 0.9630 0.9558 0.9786 
E 0.9921 0.5592 0.9644 0.9403 0.9823 0.9942 
AIC 
naproxen sodium 
R 14.82 27.45 22.68 14.70 16.85 12.20 
A 18.22 34.74 24.34 28.08 16.17 17.05 
B 16.11 30.53 24.48 17.14 15.01 14.41 
C 11.88 34.51 9.68 30.22 3.15 3.34 
D 24.53 31.28 29.87 23.92 22.06 20.43 
E 9.60 32.54 17.56 29.13 9.80 6.17 
acetaminophen 
R 18.35 26.15 25.30 15.50 10.58 13.28 
A 16.06 34.83 23.16 22.99 18.39 14.94 
B 21.33 30.34 27.46 21.49 14.26 –6.16 
C 13.23 33.96 14.77 25.44 9.91 22.15 
D 29.45 33.63 33.42 25.99 27.29 23.22 
E 12.80 33.77 20.76 22.80 13.97 11.24 
 
Table 6: Weibullʼs parameters and Td values derived from the data adjusted to this kinetic model. Mean, n = 12. *P<0.05 
Drug Product α β Fmax Td (±SEM) 
N R 43.33 1.19 105.73 22.55±0.55 
A 27.16 1.29 107.93 11.36±0.28* 
B 36.83 101.86 1.26 17.22±0.46* 
C 98.24 101.93 1.74 10.04±0.36* 
D 52.95 1.35 104.58 18.06±0.28* 
E 15.22 1.17 102.75 9.46±0.27* 
A R 116.75 1.47 99.96 25.05±0.70 
A 49.69 1.43 100.58 13.43±0.31* 
B 59.48 98.07 1.37 18.92±0.44* 
C 432.23 97.29 1.91 10.16±0.29* 
D 638.64 2.02 99.77 22.13±0.18* 
E 24.36 1.32 97.23 11.10±0.23* 
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Previously, dissolution profiles (USP Apparatus 2, 50 rpm) of 
naproxen alone have been adjusted to Korsmeyer-Peppas kinetic 
model [24]. Drug was loaded in mesoporous silica materials (ideal 
materials for encapsulation of pharmaceutical drugs) and simulated 
intestinal fluid pH = 6.8 was used as dissolution medium. Other 
authors adjusted in vitro release of naproxen to Higuchi̓s equation 
[25]. In this case, naproxen was loaded in poly-ε-caprolactone, 
nanoparticles used for extending the pharmacological action and 
reducing the frequency of administration. On the other hand, 
dissolution profiles (USP Apparatus 1, 100 rpm) of acetaminophen 
alone were adjusted to both Korsmeyer-Peppas and Higuchi'smodel 
[26]. Drug release was evaluated in silicone adhesive matrix tablets. 
Assays were carried out with simulated intestinal fluid pH = 6.8 too. 
Almost all dissolution profiles obtained in the present work, with 
commercial products, adjusted to Weibull’s kinetic model. This model 
has proven to be useful to describe in vitro release kinetics of poorly 
soluble drugs in immediate-release oral dosage forms [27‒29]. 
CONCLUSION 
1D derivative spectroscopy is a useful technique for the 
simultaneous determination of naproxen sodium and 
acetaminophen dissolution profiles from fixed-dose combinations 
formulations without interference of each other and the matrix 
effect. This method could be used for the analysis of active 
pharmaceutical ingredients in dissolution studies and for quality 
control purposes. The method is rapid, simple, and economic 
without the need of high cost investment. Considering the observed 
differences between generic drugs, it is possible to state that 
naproxen sodium and acetaminophen in fixed-dose combinations 
products are candidates to demonstrate bioavailability differences 
and therefore, it will be necessary to evaluate their in vivo 
performance before considering that they are safely 
interchangeable. 
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